



Virus-Like Particle (VLP) Vaccines against Emerging Infectious Diseases

Guest Editor:

Dr. Gang Ye

Department of Pharmacology,
University of Minnesota Twin
Cities, Saint Paul, MN 55108, USA

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editor

Emerging Infectious Diseases (EIDs) have been threatening human and animal health, causing damage to the global economy and the stability of society. Since 1940, many EID events have been reported, such as West Nile fever, Lassa fever, Ebola hemorrhagic fever, AIDS, and flu. In particular, coronavirus has shocked the world three times in the past 20 years, with the SARS strain in 2002, MERS in 2012 and COVID-19 since 2019. One of the most important strategies to prevent/treat EIDs is vaccination. Virus-Like Particle (VLP) based vaccines are a novel strategy to develop effective vaccines and show advantages over conventional vaccines. As subunit vaccines, they are safer than some conventional vaccines. VLPs better represent antigens on their surface, have high immunogenicity, and are capable of inducing both strong humoral and cellular immune responses.

This Special Issue welcomes studies (research articles and brief reports) focused on Virus-Like Particle (VLP) vaccines against emerging infectious diseases, including those caused by viruses, bacteria, parasites, and other pathogens from either humans or animals.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com